- $9.77bn
- $9.55bn
- $507.44m
U.S. STOCKS ON THE MOVE-MP Materials, Five9, Alphabet
U.S. STOCKS ON THE MOVE-MercadoLibre, CrowdStrike Holdings, Protagonist Therapeutics
Glaukos falls on wider-than-expected Q4 loss
Glaukos Corp reports results for the quarter ended December 31 - Earnings Summary
Brief: Glaukos Q4 Sales USD 105.5 Million Vs. IBES Estimate USD 100.7 Million
U.S. STOCKS ON THE MOVE-Charles River Lab, Carvana, Materion
U.S. STOCKS ON THE MOVE-Travelers, Capri, Garmin
U.S. STOCKS ON THE MOVE-Bumble, Nikola, Diversified Energy
Glaukos rises after Mizuho upgrades rating to 'outperform'
Glaukos Corp reports results for the quarter ended in September 30 - Earnings Summary
U.S. RESEARCH ROUNDUP-Cigna, Marriott, Ralph Lauren
Brief: Glaukos Q3 Sales USD 96.7 Million Vs. IBES Estimate USD 91.5 Million
Brief: Glaukos Announces Positive Topline Outcomes In Phase 3 Confirmatory Trial For Epioxa, Achieving Primary Efficacy Endpoint And Demonstrating Favorable Tolerability And Safety
U.S. RESEARCH ROUNDUP-CH Robinson Worldwide, Lam Research, Meta
Glaukos Corp reports results for the quarter ended in June - Earnings Summary
Brief: Glaukos Q2 Sales USD 95.7 Million Vs. IBES Estimate USD 88.9 Million
Glaukos Corp expected to post a loss of 51 cents a share - Earnings Preview
Brief: Glaukos Announces Agreements To Exchange $230 Million In Principal Amount Of Its 2.75% Convertible Senior Notes Due 2027 For Common Stock
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Parker-Hannifin, Quaker Houghton